Implication of External Price Referencing on Pharmaceutical list prices in Europe

Csanadi M, Prins CPJ, Grélinger E, Fricke FU, Fuksa L, Tesar T, Manova M, Lorenzovici L, Kiss A, Kaló Z

The poster was presented at the 19th ISPOR Annual European Congress, 29 Oct -2 Nov 2016, Vienna.

Read more

Collaborating Across Europe to Ensure Fair, Accessible, and Sustainable Healthcare

Who We Are

About

Participating Countries

Organisation

FAQ

What We Do

News

Activities

Data

Publications

Webinars

Get Involved

Authorities

Researchers

Stakeholders

Citizens

Newsletter

Contact

The EURIPID collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks and deliverables – a grant of the EU.

This website is part of the project ’826652 Euripid’ which is co-funded by the European Union’s Health Programme (2014-2020).

The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

© Copyright – EURIPID

Newsletter FAQ Privacy Policy
How to do External Reference Pricing by avoiding negative impact for patient...What happens to originator medicines when (generic) followers enter the public...